Drugs / LY3113593
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02604160 | Nov 2015 → Jun 2016 | chronic kidney disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02144285 | Jun 2014 → Aug 2015 | chronic renal failure syndrome | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3113593 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02144285 ↗ |
| Action | Inhibit | “LY3113593 specifically blocked BMP6 binding to its receptor” PMID 30677788 ↗ Mar 2019 |
| Modality | Monoclonal antibody | “monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKD patients.” PMID 30677788 ↗ Mar 2019 |
| Route | Intravenous | “Administered IV” NCT02144285 ↗ |
| Target | BMP6 | “monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKD patients.” PMID 30677788 ↗ Mar 2019 |